In the global intention-to-treat population, Pola-R-CHP showed significant progression-free survival benefit over R-CHOP ...

Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study. This is an ASCO Meeting ...

Authors of a recent editorial appearing in the Journal of the National Cancer Institute say opening clinical trials in ...

A phase IIA clinical trial to evaluate a reversible Bruton’s tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).

In a matched analysis involving 110 patients with transformed indolent non-Hodgkin lymphoma (TriNHL) and 391 patients with de ...

Learn the signs, symptoms, risk factors, and treatments for Hodgkin lymphoma—plus insights from a doctor who’s also a ...

Low-dose nivolumab (Opdivo) plus lenalidomide (Revlimid) yielded a promising response with a favorable safety profile in patients with classical Hodgkin lymphoma (cHL), according to a single-arm phase ...

Acalabrutinib combined with lenalidomide and rituximab shows promising results as a frontline treatment for follicular lymphoma, achieving high response rates.

Stage 3 Hodgkin’s lymphoma either indicates lymphoma in the lymph nodes both above and below a person’s diaphragm or in the lymph nodes above the diaphragm and in the spleen. Doctors may also refer to ...

Pediatric non-Hodgkin’s lymphoma (NHL) is a type of cancer that may affect children. It occurs when cells in the immune system divide uncontrollably. Symptoms can depend on where the cancer develops.